Evidence Hub

Simultaneous determination of moxifloxacin and glibenclamide in API and pharmaceutical dosage form by RP-hplc

Sania Basheer, Fatima Qamar, Sidra Yasmeen, Safila Naveed, Muhammad Tanweer Alam

The Research of Medical Science Review, 2026

Abstract

A rapid, cheap, reliable and accurate method has been developed and validated for the simultaneous analysis of Moxifloxacin and Glibenclamide in active and in dosage formulation. Glibenclamide is an antidiabetic drug belonging to the second-generation sulfonylurea. It is indicated for the management of type II diabetes mellitus. Moxifloxacin, an antimicrobial drug belongs to broad spectrum fourth generation flouroquinolone. The simultaneous analysis has been performed using Reverse-Phase High Performance Liquid Chromatography (RP-HPLC). Chromatographic separation was carried out using Purospher star C18 (5 µm, 25 × 0.46 cm) column at room temperature (25± 2 oC) with flow rate of 1 ml /min. The detector was set at 252nm and mobile phase for the experiment was 85:10:5 v/v methanol: water: acetonitrile. The correlation coefficient of both drugs was found to be > 0.990 and 0.999. The lmit of detection (LOD) and limit of quantification (LOQ) was found to be 0.02687 ng/ml, 0.02987 ng/ml and 0.08143 ng/ml, 0.09052ng/ml for moxifloxacin and glibenclamide respectively.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free